FDA Approves New Schizophrenia Treatment with a Breakthrough Mechanism

Cobenfy offers an alternative that addresses symptoms of schizophrenia with a different approach. The U.S. Food and Drug Administration (FDA) recently approved Cobenfy (xanomeline and trospium chloride) for…

Read More

Back to top
FE3